Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5638525 | 0.84 | ALDH1A1 (0.64) | ALDH1A1SMN1; SMN2GAATP53TSHR | |
| SCHEMBL5640329 | 0.82 | SMN1; SMN2 (0.46) | ALDH1A1SMN1; SMN2GAATP53TSHR | |
| SCHEMBL5637467 | 0.82 | ALDH1A1 (0.61) | ALDH1A1SMN1; SMN2GAATP53TSHR | |
| SCHEMBL5639158 | 0.81 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2GAAKDM4EPOLB | |
| SCHEMBL5637053 | 0.81 | ALDH1A1 (0.48) | ALDH1A1HPGDL3MBTL1EPHX2KDM4E | |
| SCHEMBL5640744 | 0.78 | KDM4E (0.49) | ALDH1A1SMN1; SMN2GAAKDM4E | |
| SCHEMBL5637444 | 0.77 | ALDH1A1 (0.33) | ALDH1A1SMN1; SMN2EPHX2EPHX1 | |
| SCHEMBL5638200 | 0.77 | ALDH1A1 (0.33) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL5638260 | 0.76 | ALDH1A1 (0.69) | ALDH1A1SMN1; SMN2GAATP53TSHR | |
| SCHEMBL8778504 | 0.76 | ALDH1A1 (1.00) | ALDH1A1SMN1; SMN2GAATP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7220856-B2 | Substituted quinoline CCR5 receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-05-22 | — | — | US | disclosed |
| US-20040072818-A1 | Substituted quinoline CCR5 receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072818-A1 | Substituted quinoline CCR5 receptor antagonists | CCR5, CXCR3, CCR2 | ALDH1A1 1286/4885SMN1; SMN2 4121/4885GAA 4333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.